SCHEMBL1460244

SCHEMBL1460244

NCCCCCCCNCCCN

nearest known ligand 0.93

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.93
CA6 P23280 4/20 0.93
CA7 P43166 4/20 0.93
CA9 Q16790 4/20 0.93
CA14 Q9ULX7 4/20 0.93
CA5B Q9Y2D0 4/20 0.93
CA2 P00918 3/20 0.93
CA4 P22748 3/20 0.93
CA5A P35218 3/20 0.93
F13A1 P00488 2/20 0.93
CYP1A2 P05177 2/20 0.93
ALOX15 P16050 2/20 0.93
THPO P40225 2/20 0.93
CA3 P07451 2/20 0.93
CA1 P00915 1/20 0.93
CYP2C9 P11712 1/20 0.93
PKM P14618 1/20 0.93
TSHR P16473 1/20 0.93
MTOR P42345 1/20 0.93
LMNA P02545 1/20 0.88

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1459664 1.00 CA12 (0.93) CA12CA6CA7CA9CA14
SCHEMBL6021973 1.00 CA12 (0.93) CA12CA6CA7CA9CA14
Spermine SCHEMBL28288034 1.00 CA12 (0.93) CA12CA6CA7CA9CA14
SCHEMBL28177765 1.00 CA12 (0.93) CA12CA6CA7CA9CA14
SCHEMBL13741268 1.00 CA12 (0.93) CA12CA6CA7CA9CA14
SCHEMBL818184 1.00 CA12 (0.93) CA12CA6CA7CA9CA14
Spermine SCHEMBL9331554 1.00 CA12 (0.93) CA12CA6CA7CA9CA14
SCHEMBL561079 1.00 CA12 (0.93) CA12CA6CA7CA9CA14
Spermidine SCHEMBL9144013 1.00 CA12 (0.93) CA12CA6CA7CA9CA14
SCHEMBL6514367 1.00 CA12 (0.93) CA12CA6CA7CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109843996-B Crosslinked particles 鹏达特生物科学公司 2022-09-06 CN disclosed
CN-111868146-A Composite materials comprising mechanical ligands 纳诺科尔有限公司 2020-10-30 CN disclosed
US-8729204-B2 Compositions and method for producing poly-aminofunctionalized polymerization initiators and corresponding polymers BRIDGESTONE CORPORATION (JP) 2014-05-20 US disclosed
EP-2475534-B1 COMPOSITIONS AND METHODS FOR PRODUCING POLY-AMINOFUNCTIONALIZED POLYMERIZATION INITIATORS AND CORRESPONDING POLYMERS BRIDGESTONE CORP (JP) 2013-10-23 EP disclosed
US-20120259056-A1 COMPOSITIONS AND METHOD FOR PRODUCING POLY-AMINOFUNCTIONALIZED POLYMERIZATION INITIATORS AND CORRESPONDING POLYMERS BRIDGESTONE CORPORATION (JP) 2012-10-11 US disclosed
EP-2475534-A1 COMPOSITIONS AND METHODS FOR PRODUCING POLY-AMINOFUNCTIONALIZED POLYMERIZATION INITIATORS AND CORRESPONDING POLYMERS Bridgestone Corporation (JP) 2012-07-18 EP disclosed
WO-2011031943-A1 COMPOSITIONS AND METHODS FOR PRODUCING POLY-AMINOFUNCTIONALIZED POLYMERIZATION INITIATORS AND CORRESPONDING POLYMERS BRIDGESTONE CORPORATION (JP) 2011-03-17 WO disclosed
WO-2008130721-A1 PREPARATION OF SECONDARY DIAMINES ALBEMARLE CORPORATION (US) 2008-10-30 WO disclosed
US-6043217-A ANTIBACTERIAL ACTIVITY AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA). ZAIDAN HOJIN BISEIBUTSU KAGAKU KENYU KAI (JP) 2000-03-28 US disclosed
EP-0825194-A2 An amide derivative of amythiamicin ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) 1998-02-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120259056-A1 COMPOSITIONS AND METHOD FOR PRODUCING POLY-AMINOFUNCTIONALIZED POLYMERIZATION INITIATORS AND CORRESPONDING POLYMERS PARG, PARN, PAM CA12 4322/4885CA6 4039/4885CA7 3712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.